Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T17:10:41.551Z.
Calculation as of: 2026-10-06T17:10:41.551Z.
Quote observation: 2026-10-06T17:10:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 92c64d45da0f6188a1f90128b536bb11be3c3b1eef81eadefd65dadb391e1e70
PEG RATIO
N/A
Alzamend Neuro Inc
Market Cap
$5.23M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Alzamend Neuro Inc (ALZN) | $5.23M | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.23M | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.18M | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.14M | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.30M | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.38M | N/A |
| Pulmatrix, Inc. (PULM)vs › | $5.41M | N/A |
| Imunon, Inc. (IMNN)vs › | $5.04M | N/A |
| Xenetic Biosciences, Inc. (XBIO)vs › | $5.01M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
